Affibody Hydrogels for Controlled BMP-2 Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering bone morphogenetic protein-2 (BMP-2) suffer from uncontrolled release, leading to off-target bone growth and adverse events, and existing affinity-based delivery systems face challenges in specificity, cost, and interaction predictability.
Innovation Solution
Development of affibodies with varying affinities for BMP-2, integrated into hydrogels, to control protein release and enhance specificity and stability, using directed evolution and biolayer interferometry to identify unique affibodies with distinct KDs for BMP-2.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If chemical conjugation of therapeutic proteins to biomaterials is used to control protein release, then burst release is reduced and protein presentation is prolonged, but protein-receptor binding is interfered with and biological function is altered
Solution Approach 1:
The patent introduces affibodies as intermediary molecules that mediate between the biomaterial and the therapeutic protein. These affibodies bind to the protein with controlled affinity, allowing the protein to be presented and released without direct chemical conjugation to the biomaterial, thus maintaining protein bioactivity while achieving controlled release duration
Solution Approach 2:
The patent employs affinity maturation to systematically vary and optimize the binding parameters of affibodies for different therapeutic proteins. By adjusting affinity parameters through directed evolution, the system achieves controlled protein release rates while preserving protein function, resolving the contradiction between duration of presentation and biological activity
2Duration of action of moving object
If heparin-containing delivery vehicles are used to provide intrinsic affinity for BMP-2, then sustained protein delivery is achieved, but interaction predictability is reduced due to pleiotropic interactions
Solution Approach 1:
The patent extracts the protein-binding function from heparin's pleiotropic interactions and concentrates it into affibodies specifically designed to bind target proteins. This separation allows sustained delivery through affibody-protein interactions while eliminating the unpredictable off-target interactions inherent in heparin-based systems
Solution Approach 2:
Instead of relying on the non-specific binding properties of heparin, the patent creates specific molecular copies (affibodies) that replicate the binding function with high specificity. These affibodies are engineered to provide predictable, controlled interactions with target proteins while maintaining sustained delivery capability
3Reliability
If antibodies are used for affinity-mediated protein release, then high specificity and affinity are achieved, but production cost and bulkiness increase
Solution Approach 1:
The patent segments the antibody structure into smaller affibody molecules that retain the essential binding function. By using only the minimal required structural elements for protein binding, the system achieves high specificity at a lower production cost and with reduced bulk compared to full-length antibodies
Solution Approach 2:
The patent employs affibodies as smaller, more economical alternatives to antibodies. These affibodies are cheaper to produce, can be more readily synthesized or expressed, and provide sufficient binding functionality without the high cost and complexity of full antibody production
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The affibody-conjugated hydrogels achieve controlled BMP-2 release, improving osteogenic activity and reducing adverse effects, while also being applicable for targeted delivery of other proteins like VEGF and PDGF for angiogenesis and treating diseases.
Implementation Method 1
Affinity-mediated protein release relies primarily on the equilibrium dissociation constant (KD) between the protein and material to control the rate of protein release
Implementation Method 2
the absorbable collagen sponge relies primarily on weak electrostatic interactions to physically entrap BMP-2
Data Source
AI summary
Provided are unique affibodies specific for bone morphogenetic protein 2 (BMP-2), vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), platelet-derived growth factor (PDGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), inteleukin-4 (IL-4), and glial derived neurotrophic factor (GDNF), and well as hydrogels that include the affibodies and the corresponding protein. Also provided are methods of using the hydrogels, for example to treat bone injury, wounds, and neuron injury. In some examples, the hydrogel includes at least two different affibodies specific for the same protein, but have different disassociation constants (KD). Also provided are methods of using the affibodies to treat a disease, wound, injury, or cancer.